633 related articles for article (PubMed ID: 17624657)
21. Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience.
Iida S; Kondo T; Kobayashi H; Hashimoto Y; Goya N; Tanabe K
Int J Urol; 2009 Mar; 16(3):287-92. PubMed ID: 19207115
[TBL] [Abstract][Full Text] [Related]
22. Organ preservation for muscle-invasive bladder cancer by transurethral resection.
Leibovici D; Kassouf W; Pisters LL; Pettaway CA; Wu X; Dinney CP; Grossman HB
Urology; 2007 Sep; 70(3):473-6. PubMed ID: 17905099
[TBL] [Abstract][Full Text] [Related]
23. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy.
Shariat SF; Palapattu GS; Karakiewicz PI; Rogers CG; Vazina A; Bastian PJ; Schoenberg MP; Lerner SP; Sagalowsky AI; Lotan Y
Eur Urol; 2007 Jan; 51(1):152-60. PubMed ID: 17011114
[TBL] [Abstract][Full Text] [Related]
24. Outcome of very large superficial bladder tumours: a 10-year experience.
Gupta SK; Parr NJ
Scand J Urol Nephrol; 2008; 42(3):243-8. PubMed ID: 18432531
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
Yang TB; Zeng FH; Sun ZQ
Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy.
Gupta A; Lotan Y; Bastian PJ; Palapattu GS; Karakiewicz PI; Raj GV; Schoenberg MP; Lerner SP; Sagalowsky AI; Shariat SF;
Urology; 2008 Feb; 71(2):302-7. PubMed ID: 18308108
[TBL] [Abstract][Full Text] [Related]
27. Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: a five-year follow-up.
Given RW; Parsons JT; McCarley D; Wajsman Z
Urology; 1995 Oct; 46(4):499-504; discussion 504-5. PubMed ID: 7571218
[TBL] [Abstract][Full Text] [Related]
28. Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup.
Sanderson KM; Cai J; Miranda G; Skinner DG; Stein JP
J Urol; 2007 Jun; 177(6):2088-94. PubMed ID: 17509294
[TBL] [Abstract][Full Text] [Related]
29. Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome.
Turker P; Bostrom PJ; Wroclawski ML; van Rhijn B; Kortekangas H; Kuk C; Mirtti T; Fleshner NE; Jewett MA; Finelli A; Kwast TV; Evans A; Sweet J; Laato M; Zlotta AR
BJU Int; 2012 Sep; 110(6):804-11. PubMed ID: 22321341
[TBL] [Abstract][Full Text] [Related]
30. A precystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage T2 bladder cancer.
Mitra AP; Skinner EC; Miranda G; Daneshmand S
BJU Int; 2013 Feb; 111(2):240-8. PubMed ID: 22928881
[TBL] [Abstract][Full Text] [Related]
31. Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer.
Sonpavde G; Khan MM; Lerner SP; Svatek RS; Novara G; Karakiewicz PI; Skinner E; Tilki D; Kassouf W; Fradet Y; Dinney CP; Fritsche HM; Izawa JI; Bastian PJ; Ficarra V; Schoenberg M; Sagalowsky AI; Lotan Y; Shariat SF
J Urol; 2011 Feb; 185(2):456-61. PubMed ID: 21167527
[TBL] [Abstract][Full Text] [Related]
32. Lymphovascular invasion is independently associated with poor prognosis in patients with localized upper urinary tract urothelial carcinoma treated surgically.
Saito K; Kawakami S; Fujii Y; Sakura M; Masuda H; Kihara K
J Urol; 2007 Dec; 178(6):2291-6; discussion 2296. PubMed ID: 17936818
[TBL] [Abstract][Full Text] [Related]
33. The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer.
Streeper NM; Simons CM; Konety BR; Muirhead DM; Williams RD; O'Donnell MA; Joudi FN
BJU Int; 2009 Feb; 103(4):475-9. PubMed ID: 18990174
[TBL] [Abstract][Full Text] [Related]
34. Carcinoma in a bladder diverticulum: presentation and treatment outcome.
Golijanin D; Yossepowitch O; Beck SD; Sogani P; Dalbagni G
J Urol; 2003 Nov; 170(5):1761-4. PubMed ID: 14532771
[TBL] [Abstract][Full Text] [Related]
35. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
[TBL] [Abstract][Full Text] [Related]
36. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?
Herr HW; Sogani PC
J Urol; 2001 Oct; 166(4):1296-9. PubMed ID: 11547061
[TBL] [Abstract][Full Text] [Related]
37. The risk factor for urethral recurrence after radical cystectomy in patients with transitional cell carcinoma of the bladder.
Cho KS; Seo JW; Park SJ; Lee YH; Choi YD; Cho NH; Yang SC; Hong SJ
Urol Int; 2009; 82(3):306-11. PubMed ID: 19440019
[TBL] [Abstract][Full Text] [Related]
38. Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation.
Nieder AM; Simon MA; Kim SS; Manoharan M; Soloway MS
Urology; 2006 Apr; 67(4):737-41. PubMed ID: 16618564
[TBL] [Abstract][Full Text] [Related]
39. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
Fujimoto K; Chihara Y; Kondo H; Hirao Y
Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder.
Rogers CG; Palapattu GS; Shariat SF; Karakiewicz PI; Bastian PJ; Lotan Y; Gupta A; Vazina A; Gilad A; Sagalowsky AI; Lerner SP; Schoenberg MP
J Urol; 2006 Jun; 175(6):2048-53; discussion 2053. PubMed ID: 16697800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
